YEAR-END REPORT 2015

THE FULL YEAR AND THE FOURTH QUARTER · Net sales increased to MSEK 69.1 (30.1), whereof the fourth quarter MSEK 57.4 (8.1) · Net loss was MSEK -78.2 (-59.3), whereof the fourth quarter MSEK -24.7 (-21.8) · Loss per share was SEK-1.57 (-1.60), whereof the fourth quarter SEK -0.49 (-0.59) · Cash flow from operating activities was MSEK 73.8 (-46.3), whereof the fourth quarter MSEK 120.5 (-10.7) · Cash and cash equivalents at the end of the period totalled MSEK 76.4 (51.6) · Acquisition of the companies Tanomed AB, Apropharm AS/DNE Sverige AB, Swereco Group and MedCore AB